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Introduction
Campylobacteriosis is classified as zooanthroponosis. It
is an infection caused mainly by thermophilic campylobac-
ters:  Campylobacter jejuni, Campylobacter coli, Campylo-
bacter lari, Campylobacter upsaliensis. Campylobacter je-
juni and Campylobacter coli are causing the most important
bacterial intestinal infections in modern era, with 400 000
000 patients in the world every year. A very important factor
in intestinal campylobacteriosis development is a very low
infective dosis of only 500 bacteria 
1.
Humans get infected by this bacteria consumming in-
sufficiently thermally processed meat, mostly poultry meat,
pork and beef 
2, 3, consumming unpasteurised milk and
contaminated water 
4, and beeing in contact with domestic
pets 
5. Important role of poultry in human infections is
demonstrated in Belgium during the Dioxin crisis in 1999,
when, due to high levels of poison dioxin detected, domes-
tic poultry and eggs were withdrawn from the market, re-
sulting in lowering number of campylobacteriosis cases by
40% 
2.
Thermophilic Campylobacter spp. mostly produce in-
testinal disorders, but could also produce extraintestinal dis-
orders. Gut lesions in intestinal campylobacteriosis, similar
to infections due to Salmonella and Shigella genera, are
manifested as inflammatory infiltrates in lamina propria and
abscesses in crypts 
6. The most frequent extraintestinal forms
of disease are: meningitis, endocarditis, septic arthritis, os-
teomyelitis and neonatal sepsis. Several cases of myocarditis
as a complication of Campylobacter jejuni infection were re-
ported.
Secondary diseases reported by various authors 
5, 7 as
a consequence of thermophilic Campylobacter  spp. pri-
mary infection, are Guillain-Barré syndrom (GBS) and
Reiter’s syndrom. Arthritis, GBS and Miller-Fisher’s syn-
drom (a form of GBS) are possible complications in cam-
pylobacteriosis. Campylobacteriosis is generally a mild
and self-limiting disorder. In patients with more severe
and prolonged forms, an antibiotic treatment is recom-
mended 
8.
Although a significant percentage of animals is colo-
nized, they rarely develop a disease, but they are reservoirs
of infection for humans. Poultry aged 2–3 weeks are in 50%–
90% of cases colonized by thermophilic Campylobacter
spp. 
3. Swines are less than poultry colonized by the same
bacteria. Tambur et al. 
9 demonstrated that 80.88% of poultry
and 77.27% of swines are contaminated by thermophilic
Campylobacter spp.
After inoculation to newborn calves thermophilic Cam-
pylobacter spp. produce a mild and self-limiting enteritis and
bacteriemia. Campylobacter spp. can produce dysentery in
cattle and swine 
7. Campylobacter jejuni produces abortions
in sheeps, acute enteritis in calves, dogs and cats, and hepa-
titis in poultry. Clinical symptoms of hepatitis in poultry are
somnolence, weakness, diarrhoea and eggs-laying disor-
ders 
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Treatment of campylobacteriosis and investigation
of susceptibility to antibiotics
Drugs, generally used in human campylobacteriosis
treatment are: erythromycin, quinolones, tetracyclin, ampi-
cillin, chloramphenicol and gentamycin. Disk-diffusion test,
E-test with strips and agar dilution test are used in investiga-
tions of susceptibility to antibiotics.
Different results were obtained by the three methods
applied in investigation of susceptibility 
2.
Antimicrobial susceptibility testing in Campylobacter
spp. and methodology standardization
At present, several methods have been employed for
Campylobacter susceptibility testing. Agar dilution is rec-
ommended by many authors 
8, 11, but it is time consuming
and not suitable for routine laboratory work. The E-test, a
diffusion method with MIC determination, gives results
faster than agar dilution, but its cost and need for standardi-
zation can be limitating 
12. Also, some authors recommended
broth dilution method 
13 (microbroth dilution by Trek, Vet-
Mic etc.) as suitable for routine use. Although disc diffusion
is the simplest method, absence of available standards limits
its application in clinical laboratories.
Disc diffusion and agar dilution are often compared in
order to obtain diameter zone for application in routine
work. With respect to these methods, Gaudreau and
Gilbert 
14 reported complete agreement for tetracycline and
ciprofloxacin, with only minor differences for erythromy-
cin but poor correlation coefficient for ampicillin. Simi-
larly, Luangtongum et al. 
15, revealed an excellent correla-
tion between the agar dilution and the disk diffusion for
aminoglycosidesand, quinolone/fluoroquinolones; a high-
level correlation for erythromycin, clindamycin, and tetra-
cycline, and a weak correlation for ampicillin. They sug-
gested setting the MIC breakpoint for erythromycin-
susceptible Campylobacter strains at  2 μg/mL and  8
μg/mL for resistant isolates and the zone diameter break-
points of the disk diffusion method at  23 mm for suscep-
tible isolates and  18 mm for resistant isolates. Also, they
recommended the MIC breakpoints for clindamycin to be 
2 μg/ml for susceptible isolates and  8 μg/mL for resistant
strains and the zone diameter breakpoints  17 mm for sus-
ceptible isolates and  12 mm for resistant ones. Proposed
values for the zone diameter breakpoints for tetracycline
are  28 mm for susceptible strains and  8 mm for resis-
tant strains. Authors also suggested that the disk diffusion
method can be used as a reliable alternative method for
susceptibility testing of thermophilic Campylobacter to
several classes of antimicrobial agents, particularly to
quinolone/fluoroquinolones and aminoglycosides.
Gaudreau et al. 
16 recommended zone diameters of 6
mm and  20 mm around the erythromycin disk as resistant
and susceptible breakpoints of C. jejuni isolates. Also, for
ciprofloxacin susceptibility testing of C. jejuni isolates, zone
diameters of  17 mm and  21 mm around the ciprofloxacin
disk and the absence or the presence of an inhibition zone
around the nalidixic acid disk are suggested as breakpoints
for resistance and susceptibility, respectively.
With disk diffusion, the following zone diameters were
proposed to be resistant and susceptible breakpoints, respec-
tively, for susceptibility testing of Campylobacter coli: no
inhibition zone and  15 mm for erythromycin, and  20 mm
and  25 mm for ciprofloxacin, in the absence or presence of
an inhibition zone around the nalidixic acid disk. For sus-
ceptibility testing of C. coli and C. jejuni, diameter zones 
20 mm and  26 mm for tetracycline were recommended 
17.
A recommendation, followed by these findings, is given
that disk diffusion could be used to detect C. jejuni and C.
coli isolates with reduced susceptibilities to ciprofloxacin
and erythromycin in clinical laboratories 
18.
Up to date, The Clinical and Laboratory Standards In-
stitute (CLSI), has established minimal inhibitory concentra-
tion (MIC) breakpoints for agar dilution for erythromycin,
ciprofloxacin, tetracycline and doxycycline. In addition, for
disc diffusion, zone diameter is given only for erythromycin
and ciprofloxacin 
19. EUCAST (the European Committee on
Antimicrobial Susceptibility Testing) is still working on
standards and epidemiological cut off is proposed for C. je-
juni and C. coli for erythromycin, ciprofloxacin, tetracycline,
streptomycin, gentamicin, chloramphenicol, and nalidixic
acid 
20.
Molecular techniques, also, can be applied for resistance
determination as the Mismatch Amplification Mutation Assay
(MAMA-PCR) 
21, and the Lightcycler mutation assay 
22 for
the detection of ciprofloxacin-resistant C. jejuni and C. coli
isolates. However, these and similar techniques can be ap-
plied only if prior knowledge about genetic basis for resis-
tance exist. Usually, they cannot be refered to a routine re-
sistance detection, and may not detect resistance if a new re-
sistance mechanism emerge 
22. Some authors consider that
combination of phenotypic and genotypic methods in resis-
tance detection should be more convenient 
23.
Mechanisms of erythromycin resistance in
campylobacters
Erythromycin and other macrolide antibiotics bind to
the subunit 50S of bacterial ribosome and restrict elongation
of polypeptide chain 
24. Sites for macrolide action are parts
of subunits 23S rRNA, and ribosomal proteins L4 and L22.
Proteins L4 and L22 form parts of exit channel for polypep-
tide in bacterial ribosome 70S and they are described in sev-
eral bacterial species 
25. Eyithromycin resistance can be me-
diated by enzymatic inactivation, can evolve through target
modification by mutation or methylation, and by active ef-
fluxe 
26. In Campylobacter, resistance to macrolides confer
to gene mutation with change of target site for drug binding
to bacterial ribosome 
27. Other mechanism that confer resis-
tance is active effluxe 
28. Resistance occurs as synergy be-
tween gene modification and efflux pumpe CmeABC activ-
ity 
29. Two types of resistance to macrolides are described:
resistance to high levels of drug concentration (high level re-
sistance - HLR) 
25 and resistance to lower drug concentration
(low level resistance - LLR) 
28. In HLR, MICs for erythro-Strana 202 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
Tambur Z, et al. Vojnosanit Pregl 2013; 70(2): 200–206.
mycin are higher than128 mg/L, and in LLR, MICs are in
range from 8–16 mg/L 
25, 30. In C. jejuni and C. coli strains,
HLR is a consequence of mutation in 23S rRNA V domen in
target gene at the positions 2074 and 2075. LLR can be a re-
sult of effluxe pumpe activity 
31. Also, it is recognized that
modifications of L4 and L22 contribute to low level Ery re-
sistance in C. jejuni
32.
Mechanisms of fluoroquinolones resistance in
campylobacters
Fluoroquinolones inhibit the activity of DNA gyrase
due to mutations in the DNA gyrase and DNA topoisomerase
IV genes in most bacterial species 
8. Enzyme DNA gyrase is
composed of two pairs of subunits, GyrA and GyrB, while
topoizomerase IV consists of ParC and ParE 
33. Resistance to
fluoroquinolones is a result of aminoacid changes in topoi-
somerase as well in gyrase. In Campylobacter strains, resis-
tance to fluoroquinolones is a consequence of mutation in
gene gyrA which encodes GyrA subunit of DNA gyrase 
8.
Up to date, no mutations in DNA gyrase B have been associ-
ated with FQ resistance in Campylobacter 
34. The most fre-
quently observed mutation in fluoroquinolones resistant iso-
lates of Campylobacter is the point mutation Thr-86-Ile in
gyrA gene 
35 which leads to the T86I substitution in the gy-
rase and confers HLR to fluoroquinolones 
33. Other reported
mutations of gyrA in C. jejuni include Thr-86-Ala (HLR to
nalidixic acid and LLR to ciprofloxacin), Ala-70-Thr, Thr-
86-Lys, Asp-90-Asn, and Pro-104-Ser 
35, 36. Double point
mutations of gyrA have also been reported 
35.
In  C.  jejuni and C.  coli, a unique modification in the
GyrA subunit is sufficient to confer a fluoroquinolone-
resistant phenotype. Also, decrease in permeability of outer
membrane and activity of effluxe system confer the fluoro-
quinolones resistance 
37. In Campylobacter jejuni/coli strains,
apart of the mutations in GyrA, the multidrug efflux pump,
CmeABC, also contributes to fluoroquinolones resistance by
reducing the accumulation of the agents in Campylobacter
cells 
38. Thus, CmeABC functions synergistically with the
gyrA mutations in mediating fluoroquinolones resistance 
39.
To understand the roles of multidrug efflux transporters
in the pathobiology of C. jejuni, Jean et al. 
40 characterized
the function of an MFS transporter (Cj1375) designated
CmeG. The results indicated that CmeG functions as a mul-
tidrug efflux transporter contributing to antibiotic resistance
especially to fluoroquinolones and oxidative defense in
Campylobacter.
Mechanisms of tetracyclines resistance in
campylobacters
Tetracyclines, (e.g. tetracycline, chlortetracycline, and
minocycline) bind to the ribosome and inhibit accommoda-
tion of the aminoacyl-tRNA (aa-tRNA) into the ribosomal A
site and, therefore, prevent the elongation phase of protein
synthesis 
41. Tetracycline resistance can be mediated by dif-
ferent mechanisms: efflux, the enzymatic degradation of
drug, protection of the ribosomal binding site and mutations
in 16S rDNA 
42. In C. coli and C. jejuni, genes for tetracy-
cline resistance are located on self-transmissible plasmids.
They have been identified as a ribosomal protection gene and
designated tet(O) 
43. These genes are widely present in Cam-
pylobacter isolates recovered from various animal species 
23.
They encode ribosomal protection proteins (RPPs) 
41. Tet(O)
confers resistance by binding to the ribosome inducing a
conformational change with subsequent release of the bound
tetracycline molecule and its displacing from its primary
binding site, such that the aa-tRNA can bind to the ribosomal
A site and protein synthesis can continue 
44.
The presence of tet(O) in different Gram-positive bacte-
ria 
45 suggest the origin of the resistance genes and their
sharing between species. In C. jejuni, tet(O) was first cloned
from a transferable plasmid pUA466 
46. Sequencing of two
tetracycline-resistance plasmids, one from C.  jejuni strain
81–176 
47, and other from C. coli strain CC31, revealed a
high level of sequence identity and genomic organization de-
spite their temporal and spatial distance 
48.
Although, in most strains, the tet(O) gene is plasmid-
encoded, it can be located on the chromosome, which is re-
ported for 33% of tetracycline-resistant C.  jejuni isolates
from Alberta, Canada 
49  and 76% of tetracycline-resistant
isolates from Australia Pratt, Korolik 
50. On tet(O)-carrying
plasmids it is described the presence of an insertion element
IS607 and therefore it is possible that mobile genetic ele-
ments other than transmissible plasmids may be involved in
the acquisition and dissemination of tet(O) 
51.
Tetracycline resistance in C.  jejuni is also associated
with the CmeABC multidrug efflux pump 
52.
Resistance of thermophilic Campylobacter strains
isolated from humans, poultry and swines to
erythromycin
Alarming is the rise of resistance to erythromycin, the
first choice drug for treatment of campylobacteriosis. Detec-
tion of the resistant strains started with the use of macrolides,
generally thylosine in veterinary practice, mostly in swine
farming 
8, 13, 53.
An investigation 
53 detected 12.5% Campylobacter
strains isolated from humans resistant to erythromycin.
These results are in accordance with the results of other
authors 
54–56. Lower levels of resistance to erythromycin,
ranging from 3.4% to 9.1% are reported by the authors in
Brasil, Australia, USA and India 
5, 57–59.
A tendency of rising frequency of resistant Campylo-
bacter to erythromycin is evident. For example, in Canada
there were 3% Campylobacter jejuni/coli resistant strains in
1998, but the percentage increased to 12% in 2001 
60.
A high percentage of Campylobacter jejuni/coli strains
isolated from broilers was found 
61 contrary to the fact that
erythromycin has not been used in poultry farming. A low
level of resistance to erythromycin in thermophilic Campy-
lobacter strains was recorded in Great Britain (0–8%) 
62,
USA (3.1%) 
63 and Czech Republic (6%) 
64. A high percent-
age of Campylobacter coli strains resistant to erythromycin
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was found in Japan 
65. Authors in Italy reported a high level
of resistance to erythromycin, up to 45%, in Campylobacter
coli strains isolated from poultry faeces 
55. In Africa, high
erythromycin resistance levels were observed in human
clinical isolates, but low resistance rate to this antibiotic were
noticed in C. jejuni and C. coli isolated from husbandry ani-
mals 
66. Reports from Asia describe low resistance of C. je-
juni to macrolides, but higher resistance of C. coli strains 
67.
Also, increased resistance to macrolides was observed
among C. coli isolates from pigs in Australia 
68.
Macrolides are widely used in swine farming and, as a
consequence of intensive pressure of drugs included in this
thylosine group, an increase of Campylobacter strains resis-
tant to erythromycin originating from swines occured.
The investigation detected that even 40% of thermo-
philic Campylobacter spp. strains isolated from swines were
resistant to erythromycin
 61. According to data from Spain,
percentage of resistant Campylobacter coli was 81%, in
Denmark percentage of resistant Campylobacter jejuni was
33% and of Campylobacter coli 74% 
69.
Resistance of thermophilic Campylobacter strains
isolated from humans, poultry and swines to
quinolones
A rising frequency of thermophilic Campylobacter spp.
originating from humans resistant to quinolones, drugs most
frequently used in campylobacteriosis treatment 
61, 70 is
alarming. Emergence of the resistant strains coincided with
the beginning of quinolones use in veterinary practice 
8, 71.
Thermophilic  Campylobacter spp. strains resistant to
quinolones were produced diarrhea of mean duration 13.2
days, contrary to susceptible strains with mean duration of
diarrhea of 10.3 days 
72.
Investigation of resistance to ciprofloxacin of Campy-
lobacter strains isolated from humans in Serbia, detected
50% resistance 
73. This results are in accordance to the re-
sults of others 
5, 55, 58, 74–76. In Chile the resistance of Campy-
lobacter jejuni/coli to ciprofloxacin has not been recorded 
77.
Fifty percent of thermophilic Campylobacter spp. originating
from humans were characterized as resistant to ciprofloxacin
in a controlled investigation of susceptibility to antibiotics 
73.
A high level of resistance to ciprofloxacin (71.4%) was dem-
onstrated in Campylobacter jejuni/coli isolated in India from
humans, generally children in rural areas 
58. A high level of
resistance to ciprofloxacin was registered in Spain, too. Re-
sistance to this antibiotic was found in 75% Campylobacter
jejuni and 70.7% Campylobacter coli strains 
56.
A permanent trend of resistance increase to fluoro-
quinolones is spread worldwide. Enrofloxacin is licenced in
Netherlands for use in veterinary medicine in 1987. Resistant
Campylobacter jejuni/coli strains isolated from humans rep-
resented 8% in 1998, 11% in 1989 and 29% in 1997. A
similar trend is registered in Austria, Denmark, Finland,
France, Italy, Spain, Thailand, Great Britain and USA 
8. In
Canada there were no resistance to ciprofloxacin in 1985/86.
In the following period, 1995/97, 12.7% resistant Campylo-
bacter jejuni/coli strains were isolated from humans 
60. A
high level of thermophilic Campylobacter spp. resistant to
ciprofloxacin has been registered (50% to 60%) 
55, 62, 78. Car-
dinale et al. (2002) 
70, citing several other authors, re-
portspercentages of Campylobacter jejuni/coli resistance to
ciprofloxacin in several countries: Germany 46%, Japan
46%, USA 23-100%, Kenya 7.7%, Belgium and Spain up to
100%, Taiwan and Thailand 56–84% and Senegal 34%. In
Switzerland a very low level of thermophilic Campylobacter
spp. isolated from poultry meat resistant to fluoroquinolones
is registered: only 0.5%. Resistance to ciprofloxacin in ther-
mophilic Campylobacter spp. isolated from poultry in Nor-
way was also low (2.7%). The reason for this results could
be found in the fact that fluoroquinolones were not approved
for use in broilers in Norway 
78.
Fluoroquinolones have not been applied in such extent
in swine farming as in poultry farming, this being the reason
that the percentage of Campylobacter jejuni/coli strains re-
sistant to fluoroquinolones is lower in swines than in poultry.
Results of an investigation 
79 demonstrated 26.7% resistant
Campylobacter strains isolated from swines. Similar results
were reported in Italy and Switzerland 
55, 80. A low level of
resistance to fluoroquinolones, only 0.5%, was registered in
Campylobacter jejuni/coli strains isolated from swines in
USA 
81. Hart et al. 
82 did not register a resistance to cipro-
floxacin in Campylobacter jejuni/coli isolated from swines in
Australia, due to the fact that quinolones are not approved
for use in veterinary medicine.
Resistance of thermophilic Campylobacter strains
isolated from humans, poultry and swines to
tetracyclines
It was noted that tetracyclines were used in human medi-
cine without appropriate control 
83. According to numerous
authors in the world 30%–40% thermophilic Campylobacter
strains isolated from humans are resistant to tetracycline 
73, 74.
High percentage of resistant thermophilic Campylobacter
strains isolated from humans, ranging from 43% to 85%, are
reported in Spain, USA and Finland 
54, 58, 75, 84. A lower level of
resistance to tetracycline, ranging from 12% to 16%, was re-
ported in Australia, India and Turkey 
57, 59, 76. Very low level of
thermophilic Campylobacter spp. isolated from human, resis-
tant to tetracyclines, only 1.8%, was registered in Chile 
77. The
trend of resistance increase to tetracycline in many countries is
annoying 
2, 53. Many authors report higher percentages of re-
sistance to tetracycline of thermophilic Campylobacter  spp.
strains isolated from poultry 
4, 56, 61, 65 but some reported lower
percentages of resistance 
83, 85–89. It was noted that as far as
80% strains of thermophilic Campylobacter spp. originating
from swines were resistant to tetracycline 
69, 82, 90, but some
authors registered lower percentages of resistance 
80, 81. Aar-
estrup and Wegener 
85 in Denmark, found a low resistance
level to tetracyclin in Campylobacter jejuni/coli strains iso-
lated from swines (1%).
Investigation of sensitivity to antibiotics of thermo-
philic Campylobacter spp. collected from humans, applying
disc-diffusion test, detected 47.1% strains resistant to two
antibiotics, and 11.8% strains resistant to three antibiotics 
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Hakanen et al. 
92 detected 22% Campylobacter jejuni strains
resistant to three or more antibiotics. Multiresistance to anti-
biotics of thermophilic Campylobacter spp. strains in India
was 30.6%, most fequently to erythromycin, tetracycline and
ciprofloxacin 
59.
It is necessary to emphasize recorded multiresistance of
thermophilic  Campylobacter isolated from poultry and
swines 
54, 70, 81.
Conclusion
Consuming of food contaminated with thermophilic
Campylobacter spp. results in transmission of strains resis-
tance to antibiotics and resistency genes from animals to
humans. Humans infected with strains resistant to antibiotics,
get illness with more severe symptomatology and with pro-
longed course. High level of resistance to antibiotics of
thermophilic Campylobacter spp. collected from humans and
animals, even in high industrialized countries, is a conse-
quence of irregular use and misuse of antibiotics, predomi-
nantly in veterinary medicine and husbandry, the fact dem-
onstrated in many investigations. It should be emphasized
that the level of resistance of 12.5% to erythromycin of
Campylobacter strains collected from humans and poultry
was detected, contrary to the fact that erythromycin was not
being used in poultry farming. Resistance to ciprofloxacin of
Campylobacter strains collected from humans and broilers
was 50% or more. It was demonstrated that 30% strains
originating from humans and 80% strains originating from
swines are resistant to tetracycline. A trend of resistance in-
crease to antibiotics of campylobacters collected from hu-
mans and animals is extensively evident.
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